News

FDA Alerts

Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial

03/11/2026

Stephanie Holland

Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.

Based on emerging safety data...

03/11/2026

Oncology

Conference Coverage

Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options

01/16/2026

Krish Patel, MD

Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.

Krish Patel, MD, shared results...

01/16/2026

Oncology

Videos

Subcutaneous Mosunetuzumab Demonstrates Deep, Early Responses for Treatment-Naïve Follicular Lymphoma: Phase 2 MorningSun Trial

01/08/2026

John Burke, MD

John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.

John Burke, MD, reported that...

01/08/2026

Oncology

Videos

Five-Year Data Show Durable Remissions With Tisagenlecleucel for R/R Follicular Lymphoma: ELARA Trial

01/08/2026

Stephen Schuster, MD

Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.

Stephen Schuster presented...

01/08/2026

Oncology

Conference Coverage

Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL

12/07/2025

Sairah Ahmed, MD

For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.

For patients with at least 3...

12/07/2025

Oncology

News

Real-World Safety Analysis Identifies Undocumented Adverse Events Among Patients With Follicular Lymphoma Treated With Obinutuzumab

12/03/2025

Emily Estrada

A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.

A real-world pharmacovigilance...

12/03/2025

Oncology

Videos

Emerging Targeted Therapies for Peripheral T-Cell Lymphoma

11/06/2025

Jia Ruan, MD, PhD

Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.

Jia Ruan, MD, shares insights...

11/06/2025

Oncology

News

CAR T-Cell Therapy Offers Superior Efficacy Over Bispecific Antibodies for R/R Follicular Lymphoma but With Higher Toxicity, Meta-Analysis Finds

11/05/2025

Emily Estrada

For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.

For patients with R/R FL,...

11/05/2025

Oncology

News

Fixed-Duration Epcoritamab Plus R2 Produces High Response Rates and Favorable Outcomes for R/R Follicular Lymphoma

11/05/2025

Emily Estrada

A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.

A regimen of fixed-duration...

11/05/2025

Oncology

News

CAR T-Cell Therapies Show Superior Survival Outcomes Compared to Real-World Salvage Treatments for R/R Follicular Lymphoma

11/05/2025

Emily Estrada

In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...

In a real-world setting, CAR...

11/05/2025

Oncology

Recent News

News

New Conceptual Model Captures Patient Experience in Polycythemia Vera

06/08/2026

Stephanie Holland

Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.

Results from a qualitative study...

06/08/2026

Oncology

News

Real-World Analysis Identifies Challenges With Phlebotomy-Based Management of Polycythemia Vera

06/08/2026

Stephanie Holland

Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.

Results from a retrospective...

06/08/2026

Oncology

News

Higher Starting Dose of Ropeginterferon Accelerates Responses in Patients With Polycythemia Vera

06/08/2026

Stephanie Holland

Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.

Results from a systematic review...

06/08/2026

Oncology

News

Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.

Results from the phase 3...

06/08/2026

Oncology

News

Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.

Results from a retrospective...

06/08/2026

Oncology

News

Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

06/05/2026

Emily Estrada

Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Results from a phase 1 study...

06/05/2026

Oncology

News

Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia

06/05/2026

Emily Estrada

Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.

Results from a phase 2 study...

06/05/2026

Oncology

News

Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma

06/05/2026

Emily Estrada

Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.

Results from a phase 2 study...

06/05/2026

Oncology

News

ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma

06/05/2026

Emily Estrada

Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.

Results from a phase 2 trial...

06/05/2026

Oncology

News

Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma

06/01/2026

Emily Estrada

Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.

Results from the...

06/01/2026

Oncology